Roivant Sciences Change in Accounts Payable 2021-2025 | ROIV

Roivant Sciences change in accounts payable for the twelve months ending June 30, 2025 was $-0.066B, a 805.14% decline year-over-year.

  • Roivant Sciences annual change in accounts payable for 2025 was $-0.018B, a 180.09% decline from 2024.
  • Roivant Sciences annual change in accounts payable for 2024 was $0.023B, a 420.39% increase from 2023.
  • Roivant Sciences annual change in accounts payable for 2023 was $0.004B, a 71.7% decline from 2022.

Roivant Sciences Change in Accounts Payable 2021-2025 | ROIV

  • Roivant Sciences annual change in accounts payable for 2025 was $-0.018B, a 180.09% decline from 2024.
  • Roivant Sciences annual change in accounts payable for 2024 was $0.023B, a 420.39% increase from 2023.
  • Roivant Sciences annual change in accounts payable for 2023 was $0.004B, a 71.7% decline from 2022.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.8B
Amgen (AMGN)$154.9B
Gilead Sciences (GILD)$140.2B
Vertex Pharmaceuticals (VRTX)$100.3B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.8B
CSL (CSLLY)$67.1B
Regeneron Pharmaceuticals (REGN)$61.5B
Alnylam Pharmaceuticals (ALNY)$58.5B
Argenex SE (ARGX)$43.6B
Insmed (INSM)$28.8B
BioNTech SE (BNTX)$24B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$19.4B
Incyte (INCY)$16.5B
Genmab (GNMSF)$16.5B
Genmab (GMAB)$16B
Illumina (ILMN)$15.4B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.3B
Exelixis (EXEL)$10.1B
Moderna (MRNA)$9.4B
Verona Pharma American Depositary Share (VRNA)$9.2B
Exact Sciences (EXAS)$9B
Bio-Techne Corp (TECH)$8.6B
Halozyme Therapeutics (HALO)$8.6B
Guardant Health (GH)$8.4B
Blueprint Medicines (BPMC)$8.3B